CorMedix Stock Forecast for 2023 - 2025 - 2030
Updated on 05/01/2024
CorMedix Stock Forecast and Price Target
If CorMedix's stock price reached the average yearlong target of $12.00 given by well-known analysts in recent months, there would be a potential upside of approximately 117.39% from its last closing price in May, 2024. This potential increase is based on a high estimate of $19.00 and a low estimate of $9.00. If interested in CRMD stock, you may also want to consider its competitors.
117.39% Upside
CorMedix Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, CorMedix's Price has seen an increase, rising from $0.00 to $0.00. This represents a growth of 100.00%. Analysts predict that CorMedix's Fair Value will increase in the upcoming year, reaching $5.93. This would represent an increase of 100.00%. Over the next seven years, experts predict that CorMedix's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$161.72 | Buy/Sell | $178.42 | 15.01% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$277.37 | Buy/Sell | $303.65 | 15.19% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.51 | Buy/Sell | $87.82 | 22.12% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$216.13 | Buy/Sell | $299.62 | 33.48% |
CorMedix Revenue Forecast for 2023 - 2025 - 2030
In the last two years, CorMedix has seen a decline in its Revenue, from $240.00k to $70.00k – a 70.83% decrease. Analysts predict that CorMedix's Revenue will increase in the upcoming year, reaching $23.37M. This would represent an increase of 33285.71%. Over the next seven years, experts predict that CorMedix's Revenue will grow at a rate of 481357.14%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$83.33 | Buy/Sell | $111.56 | 32.01% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$52.94 | Buy/Sell | $77.05 | 45.83% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$76.43 | Buy/Sell | $34.00 | 50.46% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$94.86 | Buy/Sell | $85.71 | 5.42% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$12.50 | Buy/Sell | $20.42 | 104.00% |
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
CorMedix EBITDA Forecast for 2023 - 2025 - 2030
CorMedix's EBITDA has grown in the last two years, jumping from $-27.09M to $-30.30M – an increase of 11.85%. In the following year, 0 experts forecast CorMedix's EBITDA will decrease by 4.64%, to $-28.89M. In 2030, professionals predict that CorMedix's EBITDA will decrease by 4.51%, to $-28.93M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.43 | Buy/Sell | $17.90 | 91.75% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$23.17 | Buy/Sell | $52.00 | 128.74% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.05 | Buy/Sell | $33.78 | 75.07% |
CorMedix EBIT Forecast for 2023 - 2025 - 2030
In the last two years, CorMedix's EBIT has increased by 12.49%, going from $-27.22M to $-30.62M. In the next year, analysts are expecting an increase in EBIT, predicting it will reach $-34.84M – an increase of 13.78%. Professionals believe that By 2030, CorMedix's EBIT will fall to $204.50M– a 767.86% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$39.35 | Buy/Sell | $63.29 | 95.68% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.08 | Buy/Sell | $42.58 | 16.82% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$33.66 | Buy/Sell | $40.00 | 29.23% |
CorMedix EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, CorMedix's EPS has seen an increase, rising from $-0.77 to $0.00. This represents a growth of 100.00%. Analysts predict that CorMedix's EPS will increase in the upcoming year, reaching $-0.74. This would represent an increase of 100.00%. Over the next seven years, experts predict that CorMedix's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.67 | Buy/Sell | $6.00 | 19.94% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.61 | Buy/Sell | $9.94 | 104.24% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.68 | Buy/Sell | $25.00 | 109.76% |
.jpg)